A dor neuropática pode ser causada por lesões e/ou disfunções no sistema somatossensorial. Nestes tipos de dores, alterações plásticas ao longo de todo o sistema sensorial nociceptivo estão associadas à cronificação do processo doloroso. A plasticidade observada pode ser resultante da indução e/ou repressão de genes, os quais geralmente são modulados por fatores de transcrição. Um dos principais fatores de transcrição até então conhecido é a proteína ativadora-1 (AP-1), que pode ser estruturalmente formado principalmente por proteínas das famílias Jun e Fos. Entretanto, na dor neuropática, a participação e o papel do AP-1 não estão bem elucidados. Dessa forma, a hipótese deste trabalho é que a ativação do AP-1 contribua para a indução e/ou manutenção da dor neuropática, através da ativação de células gliais e de proteinocinases ativadas por mitógenos (MAPK) e por indução da produção e liberação de mediadores pró-inflamatórios, bem como de metaloproteinases da matriz extracelular (MMP) na medula espinal. Esses fatores contribuem para sensibilização central causada pela SNI, facilitando a transmissão dolorosa. Assim, a inibição do AP-1 seria uma potencial estratégia terapêutica no tratamento da dor neuropática. Foi utilizado o modelo experimental de dor neuropática de lesão limitada do nervo isquiático (SNI, Spared Nerve Injury) em camundongos, os quais receberam injeção intratecal (i.t.) do inibidor de AP-1, SR11302, ou seu veículo (DMSO, tween® 20 e salina). O tratamento com o inibidor de AP-1 reduziu a hipernocicepção mecânica causada pela SNI, e o perfil de redução sugeriu que esse fator de transcrição esteja relacionado com a manutenção da dor neuropática. No sétimo dia após a SNI, observou-se na medula espinal dos camundongos, ativação da microglia, dos astrócitos e das MAPK, além de aumento na expressão de TNF-, interleucina (IL)-6, IL-1, IL-17A, quimiocina derivada de queratinócito (KC), proteína quimiotáxica de monócitos (MCP-1), óxido nítrico (NO), NO sintase induzível e das MMP-2 e -9. Todos esses eventos estão associados à sensibilização central, portanto, contribuem para a facilitação da transmissão nociceptiva. O tratamento com o inibidor de AP-1 SR11302 impediu, pelo menos parcialmente, a ativação das células gliais e das MAPK e bloqueou o aumento na expressão de todos esses mediadores pró-inflamatórios e das MMPs na medula espinal. Assim, o fator de transcrição AP-1 e, consequentemente, suas vias a jusante (downstream) são potenciais alvos farmacológicos no tratamento da dor neuropática. / Neuropathic pain results from nerve damage or dysfunction, which is associated to the painful process of chronification. This process may include participation of the inducible genes, which may be modulated by transcription factors, including the activator protein-1 (AP-1), which can structurally be formed by proteins from Jun and Fos families. However, the participation and the role of AP-1 neuropathic pain remain unclear. Our hypothesis is that the activation of AP-1 would contribute for the induction and/or maintenance of neuropathic pain, by inducing the glial cells activation and mitogen-activated protein kinases, and by inducing the production/release of pro-inflammatory mediators and extracellular matrix metalloproteinase (MMP) in mices spinal cord. All these factors are contributing to SNI-evoked central sensitization, facilitating pain transmission. Thus, inhibition of AP-1 would be a potential drug target in the treatment of neuropathic pain. The animals received inhalatory anesthesia (2% isoflurane) and were submitted to an experimental model of neuropathic pain Spared Nerve Injury (SNI). The animals were treated intrathecally (i.t.) with AP-1 inhibitor SR11302 or vehicle (DMSO, tween®20 and saline). Treatment with AP-1 inhibitor reduced the SNI-induced mechanical hypernociception, suggesting that this transcription factor is related to the maintenance of neuropathic pain. On the seventh day after SNI, there was in the spinal cord of mice microglia, astrocytes and MAPK activation, increased of expression of TNF-, interleukin (IL)-6, IL-1, IL-17A, keratinocyte-derived chemokine (KC), monocyte chemoattractant protein-1 (MCP-1), nitric oxide (NO) and inducible NO synthase, and increased the expression of MMP-2 and -9. All of these effects are related with central sensitization, thus facilitating nociceptive transmission. However, treatment with SR11302 prevented, at least partially, activation of MAPK and glial cells, as well as prevented the increase in expression of all these pro-inflammatory mediators and MMPs in the spinal cord. Thus, inhibition of AP-1 and hence its way downstream is a potential pharmacological target in the treatment of neuropathic pain.

Nos últimos anos, inúmeros avanços têm sido alcançados no que diz respeito aos mecanismos moleculares que participam na indução e manutenção da dor crônica, incluindo ativação glial. Já foi demonstrado que alguns receptores de reconhecimento padrão (PRRs), como os receptores do tipo Toll (TLRs) participam desse processo e, que em modelos de inflamação/infecção do Sistema Nervoso Central, os TLRs e os receptores do tipo NOD (NLRs) cooperam na ativação das células da glia, o que nos levou a hipotetizar que os receptores NOD1 e NOD2 também possam desempenhar um papel importante no processo de dor crônica. O NOD2 é responsável pela detecção intracelular do muramil dipeptídeo (MDP) enquanto que NOD1 reconhece o ácido diaminopimélico (iE-DAP), ambos padrões moleculares associados a patógenos (PAMPs) encontrados no peptideoglicano de bactérias. Após o reconhecimento, NLRs recrutam diretamente RIPK2 (proteína 2 de interação com o receptor RICK), uma serina-treonina quinase importante na ativação do fator nuclear kB (NF-kB). Assim, o objetivo do presente estudo foi avaliar a participação de NOD1 e NOD2, via RIPK2, no desenvolvimento da hipersensibilidade mecânica neuropática focando principalmente nos mecanismos espinais envolvidos. Dessa maneira, foi observado que os animais NOD1-/-, NOD2-/- e RIPK2-/- apresentaram redução significativa da hipersensibilidade nociceptiva mecânica quando comparado aos animais selvagens após indução de neuropatia periférica pelo modelo experimental de lesão limitada do nervo isquiático (SNI, Spared Nerve Injury). Ao contrário, a hipersensibilidade inflamatória induzida pelo adjuvante completo de Freud (CFA) não foi reduzida nesses animais. A redução da dor neuropática em NOD1-/-, NOD2-/- e RIPK2-/- foi associada a uma diminuição da expressão de IBA-1, GFAP, IL-1, TNF- e P2X4 na medula espinal quando comparado ao grupo WT. In vitro, foi observado que culturas primárias de micróglia não induziram liberação de IL-1, TNF-, IL-6 em resposta ao MDP (10g/mL) e iE-DAP (100ng/mL). No entanto, quando o MDP foi administrado juntamente com uma baixa concentração de lipopolissacarídeo (LPS) (0,1ng/mL), apresentou uma forte produção destas citocinas. Além disso, também foi demonstrado que células periféricas que infiltram na medula espinal podem expressar NOD1 e NOD2 e portanto serem capazes de induzir hipersensibilidade mecânica e ativação microglial após a indução de neuropatia. Dessa maneira, os resultados sugerem que NOD1 e NOD2, via RIPK2, contribuem para a gênese da dor neuropática, possivelmente mediando a liberação de citocinas pró-nociceptivas e a ativação de células gliais. Além disso, os resultados apontam ação potencial de NOD2 com TLR4 no intuito de estimular a ativação glial. Estes mecanismos representam uma nova abordagem para elucidar os mecanismos envolvidos na fisiopatologia da dor crônica e um possível alvo para o desenvolvimento de drogas para o tratamento da dor neuropática. / In the last years, many advances have been made related to the molecular mechanisms involved in the induction and maintenance of chronic pain, including glial activation. It has been shown that some pattern recognition receptors (PRRs) such as Toll-like receptors (TLRs) are involved in this process, and that in inflammation/infection models of the CNS, the TLRs and Nod-like receptors (NLRs) cooperate in activation of glial cells, which led us to hypothesize that NOD1 and NOD2 receptors may also play an important role in chronic pain process. NOD2 are responsible by intracellular detection of muramyl dipeptide (MDP) and NOD1 detects meso-diaminopimelic acid (iE-DAP), pathogen-associated molecular patterns (PAMPs) found in the peptidoglycan from bacteria. Upon recognition, NLRs recruit directly RIPK2, an adaptor protein, important in NLRs-mediated NFB activation. In the present study, we aimed to evaluate the participation of NOD1 and NOD2, via RIPK2, in the development of neuropathic mechanical hypersensitivity focusing mainly on spinal mechanisms involved. The results demonstrate that NOD1-/-, NOD2-/-, RIPK2-/- showed a significant reduction in mechanical hypersensitivity when compared to WT mice, after submitted to an experimental model of neuropathic pain Spared Nerve Injury (SNI). Interestingly, CFA-induced chronic inflammatory hypersensitivity was not decreased in these mice. The reduction in neuropathic pain in NOD1-/-, NOD2-/- and RIPK2-/- mice was associated with a decrease in the expression of IBA-1, GFAP, IL-1, TNF- and P2X4 in spinal cord when compared with WT. In vitro, it was observed that primary cultures of microglia did not produce IL-1, TNF-, IL-6 in response to MDP (3g/mL) or iE-DAP (100ng/mL). However, MDP, together with an ineffective concentration of LPS (0.1ng/mL), produced a robust production of these cytokines. Moreover, it was also demonstrated that peripheral cells infiltrating the spinal cord could express NOD1 and NOD2 and thus, be able to induce mechanical hypersensitivity and microglial activation after induction of peripheral neuropathy. The results suggest that NOD1 and NOD2, via RIPK2, contribute to the genesis of neuropathic pain, possibly by mediating the release of pronociceptive cytokines and increased glial cells activation. Moreover, the results indicate potential action of NOD2 with TLR4 in attempt to stimulate glial cells activation. These mechanisms represent a novel approach for elucidating the pathophysiology of chronic pain, and a target for the development of drugs for the treatment of neuropathic pain.

A dor neuropática pode ser causada por lesões e/ou disfunções no sistema somatossensorial. Nestes tipos de dores, alterações plásticas ao longo de todo o sistema sensorial nociceptivo estão associadas à cronificação do processo doloroso. A plasticidade observada pode ser resultante da indução e/ou repressão de genes, os quais geralmente são modulados por fatores de transcrição. Um dos principais fatores de transcrição até então conhecido é a proteína ativadora-1 (AP-1), que pode ser estruturalmente formado principalmente por proteínas das famílias Jun e Fos. Entretanto, na dor neuropática, a participação e o papel do AP-1 não estão bem elucidados. Dessa forma, a hipótese deste trabalho é que a ativação do AP-1 contribua para a indução e/ou manutenção da dor neuropática, através da ativação de células gliais e de proteinocinases ativadas por mitógenos (MAPK) e por indução da produção e liberação de mediadores pró-inflamatórios, bem como de metaloproteinases da matriz extracelular (MMP) na medula espinal. Esses fatores contribuem para sensibilização central causada pela SNI, facilitando a transmissão dolorosa. Assim, a inibição do AP-1 seria uma potencial estratégia terapêutica no tratamento da dor neuropática. Foi utilizado o modelo experimental de dor neuropática de lesão limitada do nervo isquiático (SNI, Spared Nerve Injury) em camundongos, os quais receberam injeção intratecal (i.t.) do inibidor de AP-1, SR11302, ou seu veículo (DMSO, tween® 20 e salina). O tratamento com o inibidor de AP-1 reduziu a hipernocicepção mecânica causada pela SNI, e o perfil de redução sugeriu que esse fator de transcrição esteja relacionado com a manutenção da dor neuropática. No sétimo dia após a SNI, observou-se na medula espinal dos camundongos, ativação da microglia, dos astrócitos e das MAPK, além de aumento na expressão de TNF-, interleucina (IL)-6, IL-1, IL-17A, quimiocina derivada de queratinócito (KC), proteína quimiotáxica de monócitos (MCP-1), óxido nítrico (NO), NO sintase induzível e das MMP-2 e -9. Todos esses eventos estão associados à sensibilização central, portanto, contribuem para a facilitação da transmissão nociceptiva. O tratamento com o inibidor de AP-1 SR11302 impediu, pelo menos parcialmente, a ativação das células gliais e das MAPK e bloqueou o aumento na expressão de todos esses mediadores pró-inflamatórios e das MMPs na medula espinal. Assim, o fator de transcrição AP-1 e, consequentemente, suas vias a jusante (downstream) são potenciais alvos farmacológicos no tratamento da dor neuropática. / Neuropathic pain results from nerve damage or dysfunction, which is associated to the painful process of chronification. This process may include participation of the inducible genes, which may be modulated by transcription factors, including the activator protein-1 (AP-1), which can structurally be formed by proteins from Jun and Fos families. However, the participation and the role of AP-1 neuropathic pain remain unclear. Our hypothesis is that the activation of AP-1 would contribute for the induction and/or maintenance of neuropathic pain, by inducing the glial cells activation and mitogen-activated protein kinases, and by inducing the production/release of pro-inflammatory mediators and extracellular matrix metalloproteinase (MMP) in mices spinal cord. All these factors are contributing to SNI-evoked central sensitization, facilitating pain transmission. Thus, inhibition of AP-1 would be a potential drug target in the treatment of neuropathic pain. The animals received inhalatory anesthesia (2% isoflurane) and were submitted to an experimental model of neuropathic pain Spared Nerve Injury (SNI). The animals were treated intrathecally (i.t.) with AP-1 inhibitor SR11302 or vehicle (DMSO, tween®20 and saline). Treatment with AP-1 inhibitor reduced the SNI-induced mechanical hypernociception, suggesting that this transcription factor is related to the maintenance of neuropathic pain. On the seventh day after SNI, there was in the spinal cord of mice microglia, astrocytes and MAPK activation, increased of expression of TNF-, interleukin (IL)-6, IL-1, IL-17A, keratinocyte-derived chemokine (KC), monocyte chemoattractant protein-1 (MCP-1), nitric oxide (NO) and inducible NO synthase, and increased the expression of MMP-2 and -9. All of these effects are related with central sensitization, thus facilitating nociceptive transmission. However, treatment with SR11302 prevented, at least partially, activation of MAPK and glial cells, as well as prevented the increase in expression of all these pro-inflammatory mediators and MMPs in the spinal cord. Thus, inhibition of AP-1 and hence its way downstream is a potential pharmacological target in the treatment of neuropathic pain.

Galliform birds (Galliformes) make up together with anseriform birds (Anseriformes) the clade Galloanserae, the sister group of Neoaves and the most basal clade of Neognathae. However, to date no quantitative data on cellular composition of their brains have been available. Here, I used the isotropic fractionator to determine numbers of neurons and non-neuronal cells in specific brain regions of 15 species of galliform birds. I find that cellular scaling rules for galliforms differ starkly from those for songbirds and parrots. When compared to these crown avian lineages, galliform birds feature lower degree of encephalization, a proportionally smaller telencephalon, small telencephalic and dominant cerebellar neuronal fractions, generally lower neuronal densities and larger glia/neuron ratios. Consequently, their brains and especially their forebrains harbor much smaller absolute numbers of neurons than those of equivalently sized songbird and parrots, the fact that undoubtedly constrains cognitive abilities of galliforms. However, this not to say that galliform birds are "bird brains" with low numbers of neurons and a limited ability to learn. Because they have high neuronal densities, their relatively small brains contain about equal numbers of neurons as brains of equivalently sized rodents and...

Les eIF2B-pathies représentent un groupe de leucodystrophies de transmission autosomique récessive du à des mutations du facteur ubiquitaire eIF2B. Celui-ci intervient dans l’initiation de la traduction et ses régulations, particulièrement en cas de stress cellulaires, grâce à son activité d’échange de guanine (GEF). Un large spectre clinique et mutationnel a été décrit pour cette pathologie.La diminution de l’activité GEF a pu être validée comme marqueur diagnostique spécifique des eIF2B-pathies dans les lymphoblastes de patients atteints avec un seuil d’activité à 77,5% pour une spécificité de 100% et une sensibilité de 89%.La compréhension des mécanismes moléculaires en cause a ensuite été recherchée selon trois approches :- une première focalisée sur l’étude de la réponse au stress du réticulum endoplasmique (RE) dans les lymphoblastes de patients eIF2B-mutés. L’hyper-activation transcriptionnelle et traductionnelle des gènes de la réponse au stress du RE, observée dans d’autres études et sur d’autres types cellulaires n’a pas été retrouvée dans cette étude.- une approche globale d’étude transcriptomique différentielle dans des fibroblastes primaires de patients eIF2B-mutés soumis ou non à un stress cellulaire. La comparaison du transcriptome avec celui de contrôles sains et de patients porteurs d’une autre leucodystrophie n’a pas permis de mettre en évidence un effet spécifique du stress dans les fibroblastes eIF2B-mutés. En revanche, il a pu être montré une dérégulation de l’expression de 70 gènes spécifiquement dans ces fibroblastes ainsi que l’implication de voies métaboliques telles que l’épissage et la stabilité des ARNm, importantes au cours du développement du système nerveux central. Ces gènes trouvés dérégulés dans les fibroblastes, appartenant notamment à la famille des hnRNP, ont été ensuite validés dans les cerveaux de patients eIF2B-mutés et une anomalie d’épissage de certains transcrits importants pour les cellules gliales a également été identifiée.- enfin, pour valider l’hypothèse d’une anomalie développementale des cellules gliales, le modèle des cellules souches embryonnaires (ESC) a été utilisé et un défaut génétique a été introduit dans ces cellules afin de mimer les mutations eIF2B. Une anomalie de différentiation de ces ESC en cellules gliales a pu être mise en évidence dans ce modèle qui pourrait alors constituer un outil de choix pour tester des molécules pouvant potentiellement améliorer la différenciation de ces cellules, principales en cause dans cette pathologie. / EIF2B-related disorders are an autosomal recessive leukodystrophy caused by mutations in the ubiquitary eIF2B factor. This one is involved in the translation initiation step and its regulation, particularly upon cellular stresses, thanks to its guanine nucleotide exchange factor (GEF) activity. A wide continuum clinical and mutational spectrum has been described for this pathology.The decrease of eIF2B GEF activity has been validated as an eIF2B-pathies specific biomarker in affected patients’ lymphoblasts with 100% specificity and 89% sensibility using a threshold at 77.5%.Functional molecular mechanisms involved in the physiopathology of eIF2B-related disorders have been searched by three approaches:- the first one focalized on the study of the endoplasmic reticulum stress response in lymphoblasts from eIF2B-mutated patients. The translational hyper-induction of specific genes involved in the unfolded protein response, identified in other cell types, was not observed in this study.- a global approach using a differential transcriptomic study of primary fibroblasts from eIF2B-mutated patients submitted or not to a cellular stress. The comparison with the transcriptomic profile of fibroblasts from healthy controls and patients presenting with other types of leukodystrophies not allowed us to identify a specific stress effect in eIF2B-mutated fibroblasts. On the other hand, it has been shown 70 genes specifically differentially deregulated in eIF2B-mutated fibroblasts as well as metabolic pathways implication, like splicing and mRNA stability, that are critical during the central nervous system development. We then validated that these genes, belonging the the hnRNP family, were also deregulated in brains from eIF2B-mutated patients and a splice abnormality of genes implicated in glial cells network has also been identified.- finally, in order to validate the hypothesis of an abnormal glial cell development, the embryonic stem cells (ESC) model has been used and a genetic default has been introduced in these cells to mimic eIF2B mutations. We identified an abnormal differentiation of these ESC into glial cells. Therefore, this model would provide a unique tool to search therapeutic agents that would improve glial cell differentiation, the major cells implicated in this pathology.

Orientadora: Márcia Rita Fernandes Machado / Banca: José Antonio Thomazini / Banca: Luiza da Silva Lopes / Banca: Áureo Evangelista Santana / Banca: Marcos Lania de Araujo / Resumo: Diversos estudos mostraram que a ingestão de dieta com níveis inadequados de ferro pode causar, no sistema nervoso central (SNC) de ratos, alterações morfológicas, bioquímicas e comportamentais no animal. Esses estudos têm ainda indicado que animais deficientes em ferro apresentam redução no número de lamelas de mielina e prejuízos na aprendizagem. A deficiência de ferro é uma das mais comuns desordens nutricionais em pacientes pediátricos e adultos e atinge cerca de 2,5 a 5 bilhões de pessoas em todo mundo. A consequência mais explícita da deficiência de ferro é a anemia. O ferro está relacionado ao desenvolvimento de fibras nervosas mielínicas, as quais constituem mais de 80% do nervo óptico. Objetivou-se, na presente investigação, avaliar com o auxílio de microscopia eletrônica de transmissão, os possíveis efeitos da anemia ferropriva na estrutura do nervo óptico de ratos Wistar durante os períodos de lactação e pós-lactação. Os animais foram divididos em 2 grupos: Controle e Anêmico. Os anêmicos receberam uma dieta com 4 mg de ferro/Kg, e os controle, uma dieta com 35 mg de ferro/Kg. Avaliações do peso corpóreo, hemoglobina e hematócrito foram feitas para checar os efeitos da deficiência de ferro. Os animais foram anestesiados com cloridrato de quetamina IM (22 mg/Kg) e então sacrificados por perfusão transcardíaca com PBS 0,05M, pH 7,4, seguido da mistura fixadora paraformaldeído 2% e glutaraldeído 1% diluída em tampão fosfato. Um segmento do nervo óptico foi retirado e pós-fixado em solução de tetróxido de ósmio a 1% por duas horas a 4ºC, desidratado em acetona e incluído em araldite. Cortes ultra-finos com 60 nanômetros de espessura foram montados em grades de cobre, contrastados com acetato de uranila e citrato de chumbo, observados e fotografados ao microscópio eletrônico de transmissão para detalhada análise ultraestrutural... (Resumo completo, clicar acesso eletrônico abaixo) / Abstract: Several studies showed that ingestion of diets with inadequate iron levels can cause morphological, biochemical and behavioral changes in the central nervous system (CNS) of rats. These studies have also shown that iron-deficient animals have reduced number of myelin lamellae and prejudice on learning. Iron deficiency is one of the most common nutritional disorders in pediatric patients and adults and affects about 2.5-5 billion people around the world. The most explicit result of iron deficiency is anemia. The iron is related to the development of myelinated nerve fibers, which constitute more than 80% of the optic nerve. The aim of this research is to evaluate, with transmission electronic microscopy, the possible effects of iron deficiency anemia in Wistar rats optic nerve structure during lactation and pos-lactation period. The animals were divided into 2 groups: Control and Anemic. The anemic group received 4 mg iron/Kg, the control group received 35 mg iron/Kg. Evaluation of body weight, hemoglobin and hematocrit were made to check the iron deficiency effects. The animals were anesthetized with ketamine 22 mg/Kg and then sacrificed by transcardiac perfusion with PBS 0.05 M, pH 7.4, followed by paraformaldehyde fixative mixture 2% and 1% glutaraldehyde. An optic nerve segment was removed and post-fixed in a solution of osmium tetroxide for two hours at 4°C, dehydrated in acetone and embedded in Araldite. Ultrathin sections with 60 nanometers thick were mounted on copper grids, contrasted with uranyl acetate and lead citrate, observed and photographed by transmission electronic microscope for detailed ultrastructural analysis of nerve fibers, blood vessels and glial cells. Both hematological and body weight were smaller in the anemic group. The ultrastructural analysis showed damaged myelinated and unmyelinated fibers, and glial cells of the anemic animals when compared with... (Complete abstract click electronic access below) / Doutor

La rupture de la barrière hémato-rétinienne interne (iBRB) se produit dans de nombreux troubles de la rétine et peut provoquer un œdème rétinien souvent responsable de la perte de vision. Le but de cette étude était de caractériser l'impact d'une rupture de l’iBRB sur les changements homéostatiques rétiniens de la dystrophine Dp71, AQP4 et Kir4.1 provoqués par les altérations les cellules gliales de Müller CGM. L'effet protecteur de la Dex a été étudié dans ce modèle. Par ailleurs, les explants rétiniens ont été utilisé pour étudier la formation et la résolution de l'œdème de CGM sans l'influence de l'inflammation du cristallin ainsi que l’effet de différentes doses de glucocorticoïdes (Dex, triamcinolone et fluocinolone) et des inhibiteurs de la voie de l'acide arachidonique. Nous avons observé que la chirurgie partielle du cristallin induit une rupture de l'iBRB et des changements moléculaires dans le CGM, une diminution de l’expression de la Dp71 et d’AQP4 et la délocalisation de Kir4.1. La Dex semble protéger la rétine par l’augmentation de l’expression du HSF1. Nous avons également observé que même si les glucocorticoides étudié ont des effets différents sur l’expression de la Dp71, AQP4 et Kir4.1 les trois sont capables de prévenir la formation de l’œdème de CGM. Nos résultats suggèrent que la formations d'œdème semblent être régulée par la voie des leucotriènes. Nous avons étudié le rôle des isoformes de la dystrophine Dp71 dans les processus d'adhésion intercellulaire des cellules PC12. Nos résultats suggèrent l’existence d’au moins deux mécanismes différents seraient impliqués dans l'adhésion intercellulaire associée à la Dp71, l'une impliquant Dp71dΔ71 et Cx43. / The breakdown of the internal blood-retinal barrier (iBRB) occurs in many retinal disorders and may cause retinal edema, often responsible for vision loss. The aim of this study was to characterize the impact of iBRB disruption on retinal homeostatic changes in Dp71 dystrophin, AQP4 and Kir4.1 caused by Müller glial cells (MGC) alterations. The protective effect of Dex has been studied in this model. In addition, retinal explants were used to study the formation and resolution of CGM edema without the influence of lens inflammation and the effect of different doses of glucocorticoids (Dex, triamcinolone and fluocinolone) and inhibitors of the arachidonic acid pathway. We observed that partial lens surgery induced iBRB breakdown and molecular changes in MGC, decreased expression of Dp71 and AQP4, and miss localization of Kir4.1. Dex seems to protect the retina by increasing the expression of HSF1. We also observed that although the glucocorticoids studied have different effects on the expression of Dp71, AQP4 and Kir4.1 all three can prevent the formation of MGC edema. Our results suggest that edema formation appears to be regulated by leukotrienes. We have studied the role of isoforms of dystrophin Dp71 in intercellular adhesion processes of PC12 cells. Our results suggest the existence of at least two different mechanisms involved in intercellular adhesion associated with Dp71, one involving Dp71dΔ71 and Cx43.

A resposta do sistema nervoso para diversas lesões acarreta a ativação das células gliais entéricas. Este trabalho tem como objetivo analisar o efeito da isquemia e reperfusão intestinal (I/R-i) sobre as células gliais entéricas, neurônios e receptores P2X2 e P2X7. Foram analisados o íleo de ratos Controle, Sham e I/R-i com 0 hora, 24 horas e 14 dias de reperfusão. Foram realizadas dupla marcação dos receptores P2X2 e P2X7 com Hu e S100, densidade, área do perfil e marcação de proliferação celular. Os resultados mostraram dupla marcação de células gliais entéricas e neurônios com os receptores P2X2 e P2X7; a densidade apresentou um aumento de células gliais e diminuição de neurônios imunorreativos ao Hu. A área do perfil de células gliais entericas S100-IR apresentaram diminuição nos grupos I/R-i e foi detectada proliferação de células gliais entéricas nos grupos I/R-i 0 hora e 24 horas. Conclui-se que a isquemia levou a alterações diferenciadas nos receptores P2X2 e P2X7, células gliais entéricas e neurônios, que podem causar disfunções gastrointestinais. / The nervous system response to various injuries involves the activation of enteric glial cells. The aim of the work was to analyze the effect of ischemia and reperfusion (I/R-i) on enteric glial cells, neurons and receptors P2X2 and P2X7. We analyzed the ileum of Control, Sham and I/R-i with 0 hour, 24 hours and 14 days of reperfusion. Double staining were performed P2X2 and P2X7 receptors with Hu and S100, density, area profile and marking of cellular proliferation. The results show double staining of neurons and enteric glial cell with the P2X2 and P2X7; density increased by glial cells and decrease of neurons immunoreactive to Hu. The area profile of enteric glial cell S100-IR showed decreased in Groups I/R-I and enteric glial cell proliferation was observed in groups I/R-i 0 hours and 24 hours. It is concluded that ischemia has led to changes in differential P2X2 and P2X7 receptors, neurons and enteric glial cells, which can cause gastrointestinal dysfunction.

Nos últimos anos, inúmeros avanços têm sido alcançados no que diz respeito aos mecanismos moleculares que participam na indução e manutenção da dor crônica, incluindo ativação glial. Já foi demonstrado que alguns receptores de reconhecimento padrão (PRRs), como os receptores do tipo Toll (TLRs) participam desse processo e, que em modelos de inflamação/infecção do Sistema Nervoso Central, os TLRs e os receptores do tipo NOD (NLRs) cooperam na ativação das células da glia, o que nos levou a hipotetizar que os receptores NOD1 e NOD2 também possam desempenhar um papel importante no processo de dor crônica. O NOD2 é responsável pela detecção intracelular do muramil dipeptídeo (MDP) enquanto que NOD1 reconhece o ácido diaminopimélico (iE-DAP), ambos padrões moleculares associados a patógenos (PAMPs) encontrados no peptideoglicano de bactérias. Após o reconhecimento, NLRs recrutam diretamente RIPK2 (proteína 2 de interação com o receptor RICK), uma serina-treonina quinase importante na ativação do fator nuclear kB (NF-kB). Assim, o objetivo do presente estudo foi avaliar a participação de NOD1 e NOD2, via RIPK2, no desenvolvimento da hipersensibilidade mecânica neuropática focando principalmente nos mecanismos espinais envolvidos. Dessa maneira, foi observado que os animais NOD1-/-, NOD2-/- e RIPK2-/- apresentaram redução significativa da hipersensibilidade nociceptiva mecânica quando comparado aos animais selvagens após indução de neuropatia periférica pelo modelo experimental de lesão limitada do nervo isquiático (SNI, Spared Nerve Injury). Ao contrário, a hipersensibilidade inflamatória induzida pelo adjuvante completo de Freud (CFA) não foi reduzida nesses animais. A redução da dor neuropática em NOD1-/-, NOD2-/- e RIPK2-/- foi associada a uma diminuição da expressão de IBA-1, GFAP, IL-1, TNF- e P2X4 na medula espinal quando comparado ao grupo WT. In vitro, foi observado que culturas primárias de micróglia não induziram liberação de IL-1, TNF-, IL-6 em resposta ao MDP (10g/mL) e iE-DAP (100ng/mL). No entanto, quando o MDP foi administrado juntamente com uma baixa concentração de lipopolissacarídeo (LPS) (0,1ng/mL), apresentou uma forte produção destas citocinas. Além disso, também foi demonstrado que células periféricas que infiltram na medula espinal podem expressar NOD1 e NOD2 e portanto serem capazes de induzir hipersensibilidade mecânica e ativação microglial após a indução de neuropatia. Dessa maneira, os resultados sugerem que NOD1 e NOD2, via RIPK2, contribuem para a gênese da dor neuropática, possivelmente mediando a liberação de citocinas pró-nociceptivas e a ativação de células gliais. Além disso, os resultados apontam ação potencial de NOD2 com TLR4 no intuito de estimular a ativação glial. Estes mecanismos representam uma nova abordagem para elucidar os mecanismos envolvidos na fisiopatologia da dor crônica e um possível alvo para o desenvolvimento de drogas para o tratamento da dor neuropática. / In the last years, many advances have been made related to the molecular mechanisms involved in the induction and maintenance of chronic pain, including glial activation. It has been shown that some pattern recognition receptors (PRRs) such as Toll-like receptors (TLRs) are involved in this process, and that in inflammation/infection models of the CNS, the TLRs and Nod-like receptors (NLRs) cooperate in activation of glial cells, which led us to hypothesize that NOD1 and NOD2 receptors may also play an important role in chronic pain process. NOD2 are responsible by intracellular detection of muramyl dipeptide (MDP) and NOD1 detects meso-diaminopimelic acid (iE-DAP), pathogen-associated molecular patterns (PAMPs) found in the peptidoglycan from bacteria. Upon recognition, NLRs recruit directly RIPK2, an adaptor protein, important in NLRs-mediated NFB activation. In the present study, we aimed to evaluate the participation of NOD1 and NOD2, via RIPK2, in the development of neuropathic mechanical hypersensitivity focusing mainly on spinal mechanisms involved. The results demonstrate that NOD1-/-, NOD2-/-, RIPK2-/- showed a significant reduction in mechanical hypersensitivity when compared to WT mice, after submitted to an experimental model of neuropathic pain Spared Nerve Injury (SNI). Interestingly, CFA-induced chronic inflammatory hypersensitivity was not decreased in these mice. The reduction in neuropathic pain in NOD1-/-, NOD2-/- and RIPK2-/- mice was associated with a decrease in the expression of IBA-1, GFAP, IL-1, TNF- and P2X4 in spinal cord when compared with WT. In vitro, it was observed that primary cultures of microglia did not produce IL-1, TNF-, IL-6 in response to MDP (3g/mL) or iE-DAP (100ng/mL). However, MDP, together with an ineffective concentration of LPS (0.1ng/mL), produced a robust production of these cytokines. Moreover, it was also demonstrated that peripheral cells infiltrating the spinal cord could express NOD1 and NOD2 and thus, be able to induce mechanical hypersensitivity and microglial activation after induction of peripheral neuropathy. The results suggest that NOD1 and NOD2, via RIPK2, contribute to the genesis of neuropathic pain, possibly by mediating the release of pronociceptive cytokines and increased glial cells activation. Moreover, the results indicate potential action of NOD2 with TLR4 in attempt to stimulate glial cells activation. These mechanisms represent a novel approach for elucidating the pathophysiology of chronic pain, and a target for the development of drugs for the treatment of neuropathic pain.

The nervous system is the most complex system in an organism. Functioning of the nervous system requires proper formation of neural cells, as well as accurate connectivity and signaling among them. While the major events that occur during these processes are known, the finer details are yet to be understood. Hence, an attempt was made to look for novel genes that could be involved in them. The focus of the present study is on CG9650, a gene that was uncovered in a misexpression screen, as a possible player in neuronal development in Drosophila melanogaster. The first chapter of the thesis reviews existing knowledge about neuronal development and function. The first section of this chapter explains in brief the formation and specification of neural stem cells, and their differentiation to neurons and glia. Sections 2 and 3 describe neuronal connectivity and signaling with respect to axon growth, synapse formation, function and plasticity. A comparison of invertebrate and vertebrate neuronal development is provided in section 4 of this chapter. This part also explains the use of Drosophila as a model for neuronal development and function. Chapter 2 describes the expression pattern of CG9650, which was characterized to gain insights into the possible role it plays during Drosophila neurogenesis.CG9650 is expressed in multiple cell types in the nervous system at the embryonic stage. Some of the cell sub-types have been identified from their morphology and position. Expression was restricted to neurons in the larval stage (except in the optic lobe, where it was expressed in precursors also), and continued in the pupal stage. No expression was seen in adults (except in the optic lobe). CG9650 has a putative DNA binding region, which bears homology to the mouse proteins CTIP1 and CTIP2, implying that CG9650 is possibly a transcription factor. In order to understand the function of CG9650, the protein was knocked down panneuronally. The resultant animals showed locomotor defects at both larval and adult stages, which have been described in chapter 3. Knock down larvae showed reduced displacement and speed of movement. The number of peristaltic cycles was also reduced in these animals but the cycle period was normal. In adults, movement was uncoordinated and righting reflex was lost, resulting in inability to walk, climb or fly. These results imply a defect in neuronal signaling. Sensory perception was unaffected in these animals. Stage specific knockdown of CG9650 indicated that the requirement for this protein is primarily during the larval stage. All CG9650-expressing neurons in the ventral nerve cord were glutamatergic, implying that its role in controlling locomotor activity is likely through glutamatergic circuits. Following up on these observations, signaling at the neuromuscular junction was assessed in CG9650 knock down animals. Chapter 4 discusses the signaling defects seen on CG9650 knock down, and the possible role of this protein. Electrophysiological recordings from Dorsal Longitudinal Muscles showed reduced and irregular neuronal firing in the knock down animals. These animals also had reduced bouton and active zone numbers. Moreover, overexpression of BRP, an active zone protein, rescued the locomotor defects caused by knock down of CG9650. Chapter 5 reports the effect of over expression of CG9650. Pan-neural over expression of CG9650 resulted in embryos with severe axon scaffolding defects, as well as aberrant neuronal and glial pattern. However, the incorrectly positioned glial cells in these embryos did not express CG9650, indicating that their aberrant positioning was probably due to incorrect signaling from the neurons. In conclusion, this study reports the requirement for CG9650, a hitherto unknown protein, in locomotor activity and signaling, thus ascribing for it a role in neuronal development and function of Drosophila melanogaster.